Universal API Implementation Guide - Local Development build (v1.1.20) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

Combo Therapies

Access Solutions/GPF Enrollments: Combination (Combo) Therapies

Some of Genentech's medicines can be used in combination with other Genentech medicines to treat a single disease. The following are common combo therapies that Access Solutions/GPF allows and which can be included within a single bundle request.

[Example AS combo therapy bundle to be added here]

Therapeutic Area (TA)	Combo Products	Product Prescribing Information Link
Oncology	Avastin and Tecentriq or Tecentriq Hybreza	Avastin
Oncology	Cotellic and Zelboraf	Cotellic
Oncology	Perjeta and Herceptin or Herceptin Hylecta	Perjeta
Oncology	Polivy and Rituxan for Oncology or Rituxan Hycela	Polivy
Oncology	Rituxan for Oncology and Rituxan Hycela	Rituxan
Oncology	Tecentriq or Tecentriq Hybreza and Cotellic and Zelboraf	Tecentriq
Oncology	Venclexta and Gazyva	Venclexta
Oncology	Venclexta and Rituxan for Oncology	Venclexta
Rheumatology	ACTEMRA Intravenous, ACTEMRA Subcutaneous, Rituxan for Immunology
Rheumatology	Rituxan for Immunology, ACTEMRA Intravenous
Rheumatology	ACTEMRA Subcutaneous, Rituxan for Immunology
Ophthalmology	Vabysmo, Susvimo, Lucentis
Ophthalmology	Vabysmo, Lucentis
Ophthalmology	Susvimo, Lucentis

Copay Enrollments: Oncology Combo Therapies

Patients can request copay assistance for combo therapies, which are determined by the primary product and FDA indication. To enroll in Copay assistance for a combo therapy, the following steps are necessary:

• Respond to the copay questionnaire for the primary product.
  
• Include the brandIds for all products in the combo therapy within a single copay bundle.
  

Example Copay request bundle for Polivy in combination with Rituxan (for Oncology)

• Primary product is Polivy, so Polivy Copay questionnaireResponse is included in bundle
  
• FDA indication = combination
  
• brandIds for Polivy and Rituxan (for Oncology) are included in the Copay bundle
  

Questionnaire Query (Primary Product)	FDA Indication	Possible Combo Drugs (included in Questionnaire Query)	Potential # of BrandIds in Bundle
Avastin	advanced nonsquamous non-small cell lung cancer hepatocellular carcinoma (HCC)	Tecentriq OR Tecentriq Hybreza	2
Cotellic	melanoma	Zelboraf Tecentriq OR Tecentriq Hybreza	3
Gazyva	combination	Venclexta	2
Herceptin	adjuvant breast cancer metastatic breast cancer	Perjeta	2
Perjeta	metastatic breast cancer neoadjuvant breast cancer adjuvant breast cancer	Herceptin OR Herceptin Hylecta	2
Polivy	combination DLBCL	Rituxan OR Rituxan Hycela OR Rituxan and Rituxan Hycela	3
Rituxan (for oncology)	recurrent or non-responsive non-hodgkins lymphoma follicular non-hodgkins lymphoma low-grade non-hodgkins lymphoma diffuse large b-cell lymphoma chronic lymphocytic leukemia	Rituxan Hycela	2
Rituxan (for oncology)	rituxan and venclexta	Venclexta	2
Rituxan (for oncology)	rituxan and polivy DLBCL	Polivy	2
Rituxan Hycela	rituxan hycela and polivy rituxan hycela and polivy first line	Polivy	2
Tecentriq	nonsquamous non-small cell lung cancer hepatocellular cancer	Avastin	2
Tecentriq	melanoma	Cotellic, Zelboraf	3
Tecentriq Hybreza	non-small cell lung cancer combo hepatocellular carcinoma	Avastin	2
Tecentriq Hybreza	melanoma	Cotellic, Zelboraf	3
Venclexta	gazyva combination	Gazyva	2
Venclexta	rituxan combination	Rituxan	2
Zelboraf	melanoma	Cotellic Tecentriq OR Tecentriq Hybreza	3